Sign in
Not yet recruitingNo phase

90Y-SIRT as Conversion Therapy for Unresectable Hepatocellular Carcinoma

Key facts

Who runs it
Beijing Tsinghua Chang Gung Hospital
Where
China6 sites in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
People taking part
200 people, planned
Starts
1 Dec 2026
Expected to end
1 Dec 2036
Type of study
Observational, 2 groups
Record updated
17 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Initially unresectable primary liver cancer
  • Underwent curative-intent hepatectomy following conversion therapy based on 90Y-SIRT or TACE
  • Postoperative histopathological examination confirmed HCC

Who cannot take part

  • Received conversion therapy based on other locoregional treatments, such as hepatic arterial infusion chemotherapy (HAIC) or external beam radiotherapy (EBRT)
  • Presence of extrahepatic metastasis prior to curative-intent hepatectomy
  • Failure to achieve R0 resection
  • Postoperative histopathological diagnosis of intrahepatic cholangiocarcinoma (ICC) or combined hepatocellular-cholangiocarcinoma (cHCC-CCA)
  • Incomplete clinical data

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This multicenter observational study will evaluate long-term outcomes in patients with initially unresectable hepatocellular carcinoma who undergo curative-intent hepatectomy after conversion therapy. The conversion therapy is based on either yttrium-90 selective internal radiation therapy or transarterial chemoembolization. The study includes a retrospective cohort and a prospective observational cohort. The primary outcome is recurrence-free survival after surgery. Overall survival, postoperative pathological features, and perioperative outcomes will also be compared between the two groups.

The 2 groups in the trial

  • 90Y-SIRT-Based Conversion Therapy Group

    Patients with initially unresectable hepatocellular carcinoma who received conversion therapy based on yttrium-90 selective internal radiation therapy (90Y-SIRT) and subsequently underwent curative-intent hepatectomy after being deemed resectable.

  • TACE-Based Conversion Therapy Group

    Patients with initially unresectable hepatocellular carcinoma who received conversion therapy based on transarterial chemoembolization (TACE) and subsequently underwent curative-intent hepatectomy after being deemed resectable.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy and Long-Term Outcomes of Yttrium-90 Treatment as Conversion Therapy for Unresectable Hepatocellular Carcinoma: A Multicenter Cohort Study
Record updated
17 November 2026